Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10239888 Targeted protein degradation using a mutant E3 ubiquitin ligase

Patent 10239888 was granted and assigned to Dana-Farber Cancer Institute on March, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

102398880

Patent Inventor Names

Mette Ishoey0

Joshiawa Paulk0

Marc Andrew Cohen0

Rhamy Zeid0

Dennis Buckley0

James Bradner0

Date of Patent

March 26, 2019

Patent Application Number

160453460

Date Filed

July 25, 2018

Patent Citations Received

‌

US Patent 12059413 Methods of inhibiting viruses using compositions targeting TSG101-ubiquitin interaction

‌

US Patent 10532103 Degradation of cyclin-dependent kinase 9 (CDK9) by conjugation of CDK9 inhibitors with E3 ligase ligand and methods of use

‌

US Patent 10669253 Methods to induce targeted protein degradation through bifunctional molecules

‌

US Patent 11583586 Methods to induce targeted protein degradation through bifunctional molecules

‌

US Patent 11059801 Methods to induce targeted protein degradation through bifunctional molecules

Patent Primary Examiner

‌

Nyeemah A Grazier

Patent abstract

The present application provides bifunctional compounds of Formula I or II:

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10239888 Targeted protein degradation using a mutant E3 ubiquitin ligase

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API